Vanguard Group Inc. Grows Stock Holdings in Relay Therapeutics, Inc. $RLAY

Vanguard Group Inc. increased its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 3.1% in the 4th quarter, Holdings Channel reports. The firm owned 9,691,445 shares of the company’s stock after buying an additional 295,701 shares during the period. Vanguard Group Inc. owned 0.06% of Relay Therapeutics worth $81,990,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Relay Therapeutics by 20.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 57,234 shares of the company’s stock valued at $484,000 after purchasing an additional 9,613 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Relay Therapeutics by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock valued at $71,000 after purchasing an additional 1,757 shares during the last quarter. Tema Etfs LLC raised its holdings in shares of Relay Therapeutics by 19.4% during the fourth quarter. Tema Etfs LLC now owns 111,555 shares of the company’s stock valued at $944,000 after purchasing an additional 18,090 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Relay Therapeutics by 9.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 65,447 shares of the company’s stock valued at $535,000 after purchasing an additional 5,704 shares during the last quarter. Finally, Congress Asset Management Co. increased its holdings in Relay Therapeutics by 1.3% during the fourth quarter. Congress Asset Management Co. now owns 414,167 shares of the company’s stock valued at $3,504,000 after buying an additional 5,325 shares during the last quarter. 96.98% of the stock is owned by hedge funds and other institutional investors.

Relay Therapeutics Trading Up 2.2%

Shares of RLAY stock opened at $13.22 on Thursday. Relay Therapeutics, Inc. has a 12 month low of $2.67 and a 12 month high of $17.32. The stock has a market cap of $2.53 billion, a P/E ratio of -8.42 and a beta of 1.74. The company has a 50 day simple moving average of $12.37 and a two-hundred day simple moving average of $9.48.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. As a group, equities analysts forecast that Relay Therapeutics, Inc. will post -1.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on RLAY. Citizens Jmp upped their target price on shares of Relay Therapeutics from $17.00 to $19.00 and gave the company a “market outperform” rating in a report on Tuesday, April 28th. The Goldman Sachs Group upped their target price on shares of Relay Therapeutics from $13.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. HC Wainwright upped their target price on shares of Relay Therapeutics from $19.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. JonesTrading began coverage on shares of Relay Therapeutics in a report on Tuesday, April 14th. They set a “hold” rating and a $18.00 target price for the company. Finally, Guggenheim upped their target price on shares of Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.56.

Insider Activity

In other news, CFO Thomas Catinazzo sold 1,800 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the completion of the sale, the chief financial officer directly owned 213,867 shares of the company’s stock, valued at $3,208,005. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,732 shares of company stock valued at $305,048 over the last three months. Corporate insiders own 5.04% of the company’s stock.

Relay Therapeutics Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.